Harvard Bioscience Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 126/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Harvard Bioscience Inc's Score
Industry at a Glance
Industry Ranking
126 / 208
Overall Ranking
295 / 4582
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
2.000
Target Price
+164.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Harvard Bioscience Inc Highlights
StrengthsRisks
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Growing
The company is in a growing phase, with the latest annual income totaling USD 94.14M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 94.14M.
Overvalued
The company’s latest PE is -0.62, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.97M shares, decreasing 25.10% quarter-over-quarter.
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Ticker SymbolHBIO
CompanyHarvard Bioscience Inc
CEODuke (John D)
Websitehttps://www.harvardbioscience.com/
FAQs
What is the current price of Harvard Bioscience Inc (HBIO)?
The current price of Harvard Bioscience Inc (HBIO) is 0.753.
What is the symbol of Harvard Bioscience Inc?
The ticker symbol of Harvard Bioscience Inc is HBIO.
What is the 52-week high of Harvard Bioscience Inc?
The 52-week high of Harvard Bioscience Inc is 2.280.
What is the 52-week low of Harvard Bioscience Inc?
The 52-week low of Harvard Bioscience Inc is 0.281.
What is the market capitalization of Harvard Bioscience Inc?
The market capitalization of Harvard Bioscience Inc is 33.59M.
What is the net income of Harvard Bioscience Inc?
The net income of Harvard Bioscience Inc is -12.40M.
Is Harvard Bioscience Inc (HBIO) currently rated as Buy, Hold, or Sell?
According to analysts, Harvard Bioscience Inc (HBIO) has an overall rating of Buy, with a price target of 2.000.
What is the Earnings Per Share (EPS TTM) of Harvard Bioscience Inc (HBIO)?
The Earnings Per Share (EPS TTM) of Harvard Bioscience Inc (HBIO) is -1.214.